Clay Siegall is the co-founder of Seattle Genetics which was formed in 1998. He is the company’s president, CEO and the chairman of the board of directors. They have been able to build a company that targets cancer and have developed several breakthroughs in that category.
The company is a leader in the antibodies technology and has developed the antibody drug conjugate platform.
He got his Ph.D. in genetics from George Washington University and a Bachelor of Science in Zoology from the University of Maryland.
He has helped the company to get financing from several avenues and has of recent gotten over $330 million from public and private financing companies. They have collaborated with several of these companies and have been able to get a worldwide network of financing and partners to help with the research.
They had an exclusive agreement with the prestigious Genentech for SGN-40 which was valued at over $860 million. These and other collaborations with other companies such as CuraGen, Bayer, MedImmune and Progenics have generated $65 million in revenues.
Where He Came From
Before he founded Seattle Genetics, he was working for Bristol-Meyer Squibb Pharmaceutical Research Institute, and before that, he was with the National Cancer Institute and then the National Institutes of Health.
Where He Works Now
He works like the board member of Alder BioPharmaceuticals which is a private biotech company. At the same time, he is involved with the Washington Biotechnology and Biomedical Association. And it does not stop there; he also is on the board of governors on the Fred Hutchison Cancer Research business Alliance.
What He Has Achieve
He has led Seattle Genetics into a new ear, and they have managed to get more than $1.2 billion in funding and financing from public and private companies that invest in their research and products.
He has won several awards that include; University of Maryland Alumnus of the Year for Computer Math and Natural Sciences in 2013, the 2012 Pacific Northwest Ernst and Young Entrepreneur of the Year. Over the years, he has published over 70 works and is the proud holder of 15 patents.
Suffice to say that he is a man who has made it in the field of genetics, biotechnology and pharmaceuticals.